% | $
Quotes you view appear here for quick access.

Nektar Therapeutics Message Board

  • typecheck typecheck Nov 15, 2012 9:28 PM Flag

    What do you think of the CV risk cited by the FDA?

    FDA seems stubborn -- "drawn a hard line on the sand" about insisting on a very large, long term CV outcome trial for Relistor. They say it is a class affect on all mu opioid antagonist. Now how is that going to affect Naloxone? All the discussion seems to center on efficacy, which I don't doubt.

17.67+0.32(+1.84%)Sep 28 4:00 PMEDT